Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 14/20 | 0.64 |
| ▸ | ANPEP | P15144 | 10/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL14583945 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL3042415 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20393806 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL14583797 | 0.80 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945874-B2 | Anti-human CD52 immunoglobulins | GENZYME CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230295338-A1 | A NOVEL ANTIBODY BINDING SPECIFICALLY TO HUMAN CEACAM1/3/5 AND USE THEREOF | YMMUNOBIO AG (CH) | 2023-09-21 | — | — | US | disclosed |
| EP-4149522-A1 | A NOVEL ANTIBODY BINDING SPECIFICALLY TO HUMAN CEACAM1/3/5 AND USE THEREOF | Ymmunobio AG (CH) | 2023-03-22 | — | — | EP | disclosed |
| US-20220010024-A1 | Anti-Human CD52 Immunoglobulins | GENZYME CORPORATION (US) | 2022-01-13 | — | — | US | disclosed |
| WO-2021228746-A1 | A NOVEL ANTIBODY BINDING SPECIFICALLY TO HUMAN CEACAM1/3/5 AND USE THEREOF | LEUKOCOM GMBH (DE) | 2021-11-18 | — | — | WO | disclosed |
| EP-3909601-A1 | A NOVEL ANTIBODY BINDING SPECIFICALLY TO HUMAN CEACAM1/3/5 AND USE THEREOF | LeukoCom GmbH (DE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3683317-A2 | ANTI-HUMAN CD52 IMMUNOGLOBULINS | Genzyme Corporation (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200040091-A1 | Anti-Human CD52 Immunoglobulins | GENZYME CORPORATION (US) | 2020-02-06 | — | — | US | disclosed |
| CN-110016081-A | Anti-human cd 52 immunoglobulins | 基酶有限公司 | 2019-07-16 | — | — | CN | disclosed |
| EP-3058955-B1 | ANTIBODIES THAT BIND OV064 AND METHODS OF USE THEREFOR | MILLENNIUM PHARM INC (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-1948691-A1 | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1868647-A2 | ANTIBODIES THAT BIND OV064 AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007085815-A2 | LIGANDS THAT BIND IL-4 AND/OR IL-13 | DOMANTIS LIMITED (GB) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007080392-A2 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR VEGF AND/OR EGFR AND METHODS OF USE THEREFOR | DOMANTIS LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007066109-A1 | BISPECIFIC LIGANDS WITH BINDING SPECIFICITY TO CELL SURFACE TARGETS AND METHODS OF USE THEREFOR | DOMANTIS LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007066106-A1 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR | DOMANTIS LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007061679-A1 | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070122404-A1 | Humanized immunoglobulin reactive with alpha4beta7 integrin | MILLENNIUM PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070003549-A1 | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor | DOMANTIS LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| WO-2006104677-A2 | ANTIBODIES THAT BIND OV064 AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |